Brief: Surface Oncology Achieves $30 Mln Milestone With First Patient Dosed In Glaxosmithkline Phase 1 Study
31/03/2022 12:42
March 31 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ACHIEVES $30 MILLION MILESTONE WITH FIRST
PATIENT DOSED IN GLAXOSMITHKLINE PHASE 1 STUDY
* SURFACE ONCOLOGY INC - WILL RECEIVE A $30 MILLION
MILESTONE
PAYMENT
* SURFACE ONCOLOGY - ELIGIBLE TO RECEIVE AN ADDITIONAL $700
MILLION IN POTENTIAL FUTURE MILESTONE PAYMENTS, AS WELL AS
TIERED ROYALTIES ON GLOBAL NET SALES
Source text for Eikon: ID:nGNX5dK6zS
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing